We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
MtQ5.0
MitoQ Research
Mostly mechanism / observational
26 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most MitoQ studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2010–2026 with a typical study size of 25 participants.
Based on 26 studies · 2 meta-analyses · 18 RCTs · 246 total participants
Confidence
High confidence
By outcome
Aging & healthspan (emerging)Mitochondrial-ROS rationale for vascular aging; human data are surrogate markers, not lifespan · Long-term
Endurance & exercise performanceAcute vascular/exercise-tolerance gains in PAD, but null effect on endurance-training adaptation in healthy adults · Mixed
Mostly mechanism / observational4 studies
Neuroprotection & brain agingMechanistic appeal, but the largest Parkinson's RCT found no disease-modifying effect · Unproven
Too few graded studies2 studies
Liver health
Too few graded studies1 study
Active research area
18 studies in the last 5 years · Latest meta-analysis: 2022
201020182026
1Meta-Analysis2018
Braakhuis AJ, Nagulan R, Somerville V · Oxid Med Cell Longev (2018)
In plain English: Future research should investigate whether MitoQ supplementation concurrent with exercise training (e.g., 4-16 weeks) alters adaptations induced by exercise alone and using different doses.
Gonzalo-Skok O, Casuso RA. · Sports medicine - open (2024)
Our findings indicate that MitoQ supplementation effectively reduces exercise-induced oxidative damage (SMD: -1.33; 95% CI: -2.24 to -0.43).
Furthermore, our findings indicate that acute and/or chronic MitoQ supplementation does not improve endurance exercise performance (SMD: -0.50; 95% CI: -1.39 to 0.40) despite reducing exercise-induced oxidative stress.
Notably, our sensitivity analysis reveals that MitoQ may benefit subjects with peripheral artery disease (PAD) in improving exercise tolerance.
In plain English: Conclusion The synthesis of these findings illustrated a broad spectrum of benefits ranging from enhanced insulin secretion to improved lipid profiles and mitochondrial function, yet the path to clinical application required further investigation on appropriate doses and populations.
Pang M, Wang S, Shi T, Chen J. · Frontiers in cardiovascular medicine (2025)
Methods This scoping review aimed to synthesize current research on the health impacts of MitoQ on CMD, focusing primarily on human-based clinical trials.
While the primary focus was on human trials, in vivo and in vitro studies were referenced as supplementary material to provide a broader understanding of MitoQ's mechanisms and potential effects.
Results This scoping review had synthesized the findings that collectively contributed to the understanding of mitochondrial-targeted antioxidants and their role in CMD.